ArticleTransboundary and emerging diseases2025
Pathogenic and Antigenic Analyses of H5N1 High Pathogenicity Avian Influenza Virus Isolated in the 2022/2023 Season From Poultry Farms in Izumi City, Japan.
Article in Transboundary and emerging diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Genetic Diversity of Clade 2.3.4.4b H5Nx high pathogenicity Avian Influenza Viruses detected in Korea during the 2025-2026 winter season and pathogenicity of H5N1 and H5N9 viruses.Virus research · 2026Article
- Avian Influenza at the Wild Bird-Poultry Interface: An Asia-Focused Review with Ecological Risk Scenarios for China.Animals : an open access journal from MDPI · 2026Review
- Influenza A Virus H5N1 Subtype: Resurgent Interspecies and Intercontinental Transmission, and a New Host.Pathogens (Basel, Switzerland) · 2025Review
- Genetic Diversity of Highly Pathogenic Avian Influenza Viruses Isolated in Hokkaido, Japan, During Winter 2024-2025.Pathogens (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the winter of 2022/2023, Japan experienced its largest outbreak of high pathogenicity avian influenza (HPAI), affecting 84 poultry premises. In this study, we investigated the pathogenicity and antigenicity of A/chicken/Kagoshima/22A1T/2022 (Kagoshima/22A1T), a clade 2.3.4.4b H5N1 virus belonging to the G2b group. It was isolated from a poultry farm in Izumi City, where the largest number of consecutive cases was recorded. The 50% lethal dose, mean death time (MDT), amount of virus shed, and transmissibility in chickens of Kagoshima/22A1T were similar to those of A/chicken/Kagoshima/21A6T/2022 (Kagoshima/21A6T), the previous season's isolate of the same group, indicating that their pathogenicities were comparable. However, the antigenicity of these isolates differed according to the hemagglutination inhibition (HI) test results. We found that the amino acid substitutions in residues 189 and 193, corresponding to antigenic site B in the H3 virus of the HA1 subunit, could have an impact on the HI cross-reactivity of Kagoshima/21A6T. This study provides important insights into the factors contributing to the consecutive HPAI outbreaks on poultry farms in Izumi City during the 2022/2023 season and the prediction of antigenic changes in G2b group HPAI viruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.